Closing the Gaps in NSCLC

Not only is lung cancer the leading cause of cancer deaths among females and males, but it’s also the most common type of cancer. Despite its high prevalence and mortality rates, communicative care between non-small cell lung cancer (NSCLC) patients and their providers is still unfortunately lacking.
In an effort to both address and resolve this disparity, Closing the Gaps in NSCLC will focus on the latest guidelines and the current therapeutic landscape within NSCLC.
This non-certified educational series is sponsored by Lilly. Content for this series is produced and controlled by ReachMD. This series is intended for healthcare professionals only.
Sponsored by

Episodes 1-16 of 27

- Deepa Rangachari, MD
  Peer
1
Closing the Gaps in NSCLC
Fulfilling the Unmet Needs of NSCLC Patients
Fulfilling the Unmet Needs of NSCLC Patients
Fulfilling the Unmet Needs of NSCLC Patients
- Deepa Rangachari, MD
  Peer
1
Closing the Gaps in NSCLC
On the Forefront of NSCLC Treatment: Targeting RET Mutations
On the Forefront of NSCLC Treatment: Targeting RET Mutations
On the Forefront of NSCLC Treatment: Targeting RET Mutations
- Deepa Rangachari, MD
  Peer
1
Closing the Gaps in NSCLC
The Importance of Symptom Management for NSCLC Patients
The Importance of Symptom Management for NSCLC Patients
The Importance of Symptom Management for NSCLC Patients
- Jennifer Caudle, DO
  Peer
- Deepa Rangachari, MD
  Peer
1
Closing the Gaps in NSCLC
New Approaches to Treating Non-Small Cell Lung Cancer
New Approaches to Treating Non-Small Cell Lung Cancer
New Approaches to Treating Non-Small Cell Lung Cancer
- Joshua M. Bauml, MD
  Peer
0
Closing the Gaps in NSCLC
How COVID-19 Has Impacted the Care Continuum for NSCLC Patients
How COVID-19 Has Impacted the Care Continuum for NSCLC Patients
How COVID-19 Has Impacted the Care Continuum for NSCLC Patients
- Joshua M. Bauml, MD
  Peer
0
Closing the Gaps in NSCLC
RET Fusions vs. RET Point Mutations: Understanding the Difference
RET Fusions vs. RET Point Mutations: Understanding the Difference
RET Fusions vs. RET Point Mutations: Understanding the Difference
- Mario R. Nacinovich, Jr., MSc
  Peer
- Lyudmila Bazhenova, MD
  Peer
0
Closing the Gaps in NSCLC
Targeting Oncogenic Drivers in NSCLC: Opportunities & Challenges
Targeting Oncogenic Drivers in NSCLC: Opportunities & Challenges
Targeting Oncogenic Drivers in NSCLC: Opportunities & Challenges
- Joshua M. Bauml, MD
  Peer
0
Closing the Gaps in NSCLC
Exploring RET-Targeted Cancer Diagnosis & Treatment Strategies
Exploring RET-Targeted Cancer Diagnosis & Treatment Strategies
Exploring RET-Targeted Cancer Diagnosis & Treatment Strategies
- Joshua M. Bauml, MD
  Peer
1
Closing the Gaps in NSCLC
What to Consider When Testing for Oncogenic Drivers in NSCLC
What to Consider When Testing for Oncogenic Drivers in NSCLC
What to Consider When Testing for Oncogenic Drivers in NSCLC
- Joshua M. Bauml, MD
  Peer
0
Closing the Gaps in NSCLC
Mechanisms of Acquired Resistance to Targeted Therapies in NSCLC
Mechanisms of Acquired Resistance to Targeted Therapies in NSCLC
Mechanisms of Acquired Resistance to Targeted Therapies in NSCLC
- Fred R. Hirsch, MD, PhD
  Peer
0
Closing the Gaps in NSCLC
The Role of Oncogene Addiction in RET Mutations & Treatment Selection
The Role of Oncogene Addiction in RET Mutations & Treatment Selection
The Role of Oncogene Addiction in RET Mutations & Treatment Selection
- Mario R. Nacinovich, Jr., MSc
  Peer
- Gregory J Kubicek, MD
  Peer
1
Closing the Gaps in NSCLC
Emerging Technologies for Treating Non-Small Cell Lung Cancer
Emerging Technologies for Treating Non-Small Cell Lung Cancer
Emerging Technologies for Treating Non-Small Cell Lung Cancer
- Jacob Sands, MD
  Peer
2
Closing the Gaps in NSCLC
Next Generation Sequencing in Lung Squamous Cell Carcinoma
Next Generation Sequencing in Lung Squamous Cell Carcinoma
Next Generation Sequencing in Lung Squamous Cell Carcinoma
- Jacob Sands, MD
  Peer
0
Closing the Gaps in NSCLC
Innovations in Screening Modalities for NSCLC
Innovations in Screening Modalities for NSCLC
Innovations in Screening Modalities for NSCLC
- Jonathan Riess, MD, MS
  Peer
0
Closing the Gaps in NSCLC
Managing Toxicities in the NSCLC Care Continuum: Multidisciplinary Touchpoints
Managing Toxicities in the NSCLC Care Continuum: Multidisciplinary Touchpoints
Managing Toxicities in the NSCLC Care Continuum: Multidisciplinary Touchpoints
- Jacob Sands, MD
  Peer
0
Closing the Gaps in NSCLC
Counseling Strategies in NSCLC Care: Helping Patients Cope with a Diagnosis
Counseling Strategies in NSCLC Care: Helping Patients Cope with a Diagnosis
Counseling Strategies in NSCLC Care: Helping Patients Cope with a Diagnosis

Prev
1
2
Next

1/2

Applying Real-World Evidence to Improve Clinical Decision-Making for Patients with HR-positive/HER2-negative Metastatic Breast Cancer

Javier Cortes, MD, PhD

Applying Real-World Evidence to Improve Clinical Decision-Making for Patients with HR-positive/HER2-negative Metastatic Breast Cancer

Learn More

Applying Real-World Evidence to Improve Clinical Decision-Making for Patients with HR-positive/HER2-negative Metastatic Breast Cancer

UP NEXT...

Components to a Comprehensive Lung Cancer Screening Program

Guest
Jacob Sands, MD